Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

March 2017

Stelara Coverage and Prior Authorization Criteria Updated


Effective for dates of service on or after April 15, 2017, Harvard Pilgrim is updating our Stelara commercial and StrideSM (HMO) Medicare Advantage prior authorization policies to include additional criteria for the use of Stelara to treat plaque psoriasis and psoriatic arthritis and to add Crohn’s disease as a covered indication.

Harvard Pilgrim covers Stelara for the treatment of certain adults with moderate-to-severe plaque psoriasis or psoriatic arthritis with prior authorization. Effective April 15, coverage criteria will include the following:

  • Previous treatment failure, inadequate response, contraindication (per FDA label), intolerance, or not a candidate for anti-tumor necrosis factor (TNF) biologic therapy with adalimumab (Humira™) or etanercept (Enbrel®)

In addition, Harvard Pilgrim will begin covering Stelara to treat severely active Crohn’s disease when the treatment is reasonable and medically necessary and all prior authorization criteria have been met.

To request prior authorization, please fax one of the following to 800-232-0816: a completed Massachusetts Standard Form for Medication Prior Authorization Requests if you are a Massachusetts provider or a completed Immune Modulating Drugs Prior Authorization Request form if you practice in state.

For complete information, refer to the updated commercial Stelara Medical Review Criteria and StrideSM (HMO) Medicare Advantage Stelara Medical Review Criteria.
 
Stelara is also offered through Harvard Pilgrim’s pharmacy benefit, and the associated Stelara Clinical Coverage Criteria have been updated to reflect these changes, effective April 15, 2017. When requesting authorization through the pharmacy benefit, providers in Massachusetts should complete the Massachusetts Standard Form for Medication Prior Authorization Requests, including any supplementary information that may be useful in the “Additional information pertinent to this request” section, and fax it to MedImpact Healthcare Systems at 888-807-6643. Providers in all other states should complete the updated Stelara Medication Request Form and fax it to MedImpact Healthcare Systems at 888-807-6643.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

National Healthcare Decisions Day Emphasizes Advance Care Planning

The Foundation’s Report on Transgender Health Care in Greater Boston

CLINICIAN CORNER

Stelara Coverage and Prior Authorization Criteria Updated

Update: Pudendal Nerve Decompression Coverage

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS Measure

OFFICE ASSISTANT

Appropriate Use of Modifier 91

Harvard Pilgrim Expanding Authorization ID Numbers

Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator